𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer

✍ Scribed by Lars E. Rutqvist; Björn Cedermark; Ulla Glas; Hemming Johansson; Sam Rotstein; Lambert Skoog; Anders Somell; Tolle Theve; Nils Wilking; Jutta Askergren; Marie-Louise Hjalmar

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
721 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized trial of long term adjuvant
A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery
✍ Kristina Dalberg; Hemming Johansson; Ulla Johansson; Lars E. Rutqvist 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

## BACKGROUND. The use of adjuvant tamoxifen to treat postmenopausal breast carcinoma patients as an adjunct to primary surgery is well established. The current study reports the long term results for a low risk stratum in a randomized trial of adjuvant tamoxifen. The main focus of this analysis w

Anastrozole alone or in combination with
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses
✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d

Randomized adjuvant trial to evaluate th
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization
✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

Do adjuvant aromatase inhibitors increas
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer : Meta-analysis of randomized trials
✍ Federica Cuppone; Emilio Bria; Sunil Verma; Kathleen I. Pritchard; Sonal Gandhi; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 1 views

## Abstract ## BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada‐Common Toxicity Criteria [version

The effect of postoperative and primary
The effect of postoperative and primary radiation therapy on delivered dose of adjuvant Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy in breast cancer
✍ Jedd F. Levine; C. Norman Coleman; Richard S. Cox; Gordon R. Ray; William M. Rog 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 457 KB 👁 2 views

The dose of adjuvant chemotherapy for breast cancer may be an important factor in the success of the treatment program. In a retrospective analysis, the authors determined whether patients who were irradiated either postoperatively (N = 29) or as part of primary treatment (N = 13) received a lower d